Interim Procurement Specialist
PharmaEssentia U.S.A.
Bedford, MA•Est. $75-$125/hr
Inventory ManagementContract ManagementDirector of Supply ChainNegotiation
PharmaEssentia U.S.A.
PharmaEssentia creates novel MPN treatments like Ropeginterferon alfa-2b. Operating certified facilities, it targets global markets directly and via licensing.
- Est. revenue
- $20M–$50M
- Total raised
- $463M
- Latest round
- Post-IPO Equity
- Employees
- 478
Funding & revenue at PharmaEssentia U.S.A.
How well capitalized the business is — useful context before you scope a fractional engagement or negotiate a rate.
Estimated annual revenue
$20M–$50M
Modeled range, not company-reported
Total capital raised
$463M
1 known investor
Latest round
Post-IPO Equity · $463M
Apr 2023
Publicly traded
PHARMAESSENTIA, 6446
IPO Jan 2024
Investors
Taiwania Capital Management Corporation
Growth signals
How fast PharmaEssentia U.S.A. is adding people, roles, and audience.
Employees
478
Reported band 501-1000
Open roles
2
-0.8% year over year
LinkedIn followers
28.4K
+65.6% year over year
Headcount change
- MoM
- +1.5%
- QoQ
- +7.7%
- 6mo
- +21.9%
- YoY
- +28.8%
- 2yr
- +49.8%
+7 people
+34 people
+86 people
+107 people
+159 people
Team composition
Where PharmaEssentia U.S.A. concentrates its people — a read on which function a fractional leader would plug into.
By function
- Research9019%
- Sales8518%
- Business Development4910%
- Information Technology225%
- Healthcare Services214%
- Operations194%
- Human Resources184%
- Quality Assurance174%
By region
- United States264
- Taiwan158
- Greater Boston96
- Massachusetts, United States92
- Taipei–Keelung Metropolitan Area77
- Taipei City, Taiwan60
Inside PharmaEssentia U.S.A.
What the business focuses on, where it operates, and how employees rate it.
Specialties
BiologicsOncologyRare DiseaseOrphan DrugsOrphan DiseaseDrug DevelopmentPharmaceuticalsHematology
Categories
BiotechnologyHealth CarePharmaceuticalBiotech & PharmaceuticalsPharmaceutical and biotechnology
Markets
TPE
Offices
- 2F-5, No. 3, Park Street, Nangang District, Taipei, 115, TW
- , Tokyo, Tokyo, 100-0000, JP
- , Beijing, Beijing, 100000, CN
- , Bedford, MA, 01730, US
Competitors
Companies in the same market as PharmaEssentia U.S.A..
http://maiapharma.comhttp://en.metabiopharma.com/http://www.leukosbiotech.comhttp://www.optherion.comhttp://www.pasithea.comhttps://www.appliedneurosolutions.nethttp://www.principiabio.comhttp://www.elthera.com/http://www.ascelia.comhttps://www.pharmion.com/http://www.ampiopharma.comhttp://hemispherian.comhttp://www.heidelberg-pharma.comhttps://www.pleopharma.com/http://nephrodi.comhttp://asteriasbiotherapeutics.com/
PharmaEssentia U.S.A. in the news
Recent coverage picked up alongside the firmographic refresh.
- PharmaEssentia to Present at the Society of Hematologic Oncology (SOHO) 2026 Annual Meeting
Sep 2026
- PharmaEssentia's August Revenue Doubles to Record High; US and Japan ET Approvals Secured, Set to Rejoin Taiwan Top 50 Index in September
Sep 2026
- PharmaEssentia wins first FDA nod for essential thrombocythemia in nearly 30 years
Sep 2026
- PharmaEssentia Gets US FDA's Approval for Essential Thrombocythemia Treament Drug; Shares Sink 10%
Aug 2026
- ICC Arbitral Tribunal Issues Quantum Award for AOP Health in BESREMi® Proceedings
Aug 2026
- Merck Pill Becomes First Oral Option in Growing Class of Cholesterol-Lowering Drugs
Jul 2026
Jobs
1Funding, revenue, headcount, and hiring figures are third-party estimates from public sources and are not confirmed by the company. Last refreshed September 25, 2026.
About this page
This company page is automatically generated based on publicly available job postings. Company information is sourced from publicly available data and may not be complete. If you represent PharmaEssentia U.S.A., you can claim this page to manage and enhance it.